Burning rock presents latest clinical data from thunder study at 2022 asco annual meeting

Shanghai , june 15, 2022 /prnewswire/ -- burning rock (nasdaq:bnr) presented the final results from the multi-center case-control thunder study (the unintrusive detection of early-stage cancer, nct04820868) in a poster entitled "unintrusive multi-cancer detection by circulating cell-free dna methylation sequencing (thunder): development and independent validation studies" at the 2022 american society of clinical oncology (asco) annual meeting. this is a comprehensive review of clinical performance after the four-year thunder study.
BNR Ratings Summary
BNR Quant Ranking